U.S. markets open in 5 hours

Foghorn Therapeutics Inc. (FHTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.79-0.25 (-2.26%)
At close: 04:00PM EST
10.79 0.00 (0.00%)
After hours: 04:01PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close11.04
Bid0.00 x 900
Ask0.00 x 800
Day's Range10.48 - 11.22
52 Week Range8.01 - 28.26
Avg. Volume62,245
Market Cap400.218M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.69
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for FHTX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Foghorn Therapeutics Inc.
    Daily – Vickers Top Buyers & Sellers for 12/01/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    Foghorn Therapeutics to Participate at the 2021 Jefferies London Healthcare Conference

    CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate virtually at the 2021 Jefferies London Healthcare Conference. 2021 Jefferies London Healthcare ConferenceFormat: Virtual presentation and investor 1x1 meetingsThe presentation will

  • GlobeNewswire

    Foghorn Therapeutics Provides Third Quarter 2021 Corporate Update

    -- First patient dosed in phase 1 clinical trial of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma -- Continue to enroll patients in phase 1 clinical trials of FHD-286, an inhibitor of BRG1/BRM, in metastatic uveal melanoma and relapsed or refractory acute myeloid leukemia (AML) -- Presented an overview of Company’s proprietary protein degrader platform and clinical stage asset, FHD-609, at the 4th Annu

  • Insider Monkey

    10 Pharmaceutical Stocks to Buy According to Jim Simons’ Euclidean Capital

    In this article, we reviewed Jim Simons’ investment strategy, historical performance, and family office portfolio. We also examined 10 pharmaceutical stocks to buy according to Jim Simons’ Euclidean Capital. You can skip our detailed discussion and jump directly to the 5 Pharmaceutical Stocks to Buy According to Jim Simons’ Euclidean Capital. Known as “Quant King”, […]